Walleye Capital LLC Buys Shares of 11,721 Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Walleye Capital LLC purchased a new position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 11,721 shares of the company’s stock, valued at approximately $187,000.

Other institutional investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after buying an additional 826 shares during the period. GAMMA Investing LLC boosted its position in shares of Centessa Pharmaceuticals by 103.1% in the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after acquiring an additional 1,509 shares during the last quarter. Quarry LP grew its holdings in Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after purchasing an additional 3,108 shares during the period. Sandia Investment Management LP acquired a new position in Centessa Pharmaceuticals during the second quarter worth approximately $90,000. Finally, Fred Alger Management LLC purchased a new position in Centessa Pharmaceuticals during the second quarter worth approximately $99,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 11,742 shares of the company’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $15.38, for a total transaction of $180,591.96. Following the sale, the insider now directly owns 183,266 shares of the company’s stock, valued at approximately $2,818,631.08. This represents a 6.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Saurabh Saha sold 87,496 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $18.46, for a total transaction of $1,615,176.16. Following the sale, the chief executive officer now directly owns 575,661 shares of the company’s stock, valued at approximately $10,626,702.06. The trade was a 13.19 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 262,624 shares of company stock worth $4,497,698. 11.59% of the stock is currently owned by insiders.

Analyst Ratings Changes

CNTA has been the topic of a number of research reports. Oppenheimer restated an “outperform” rating and issued a $14.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. B. Riley assumed coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $11.00 to $26.00 in a research note on Thursday, September 19th. BMO Capital Markets raised their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Finally, Jefferies Financial Group upped their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Centessa Pharmaceuticals has an average rating of “Buy” and an average target price of $25.83.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $17.18 on Thursday. Centessa Pharmaceuticals plc has a 12-month low of $6.15 and a 12-month high of $18.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of -11.23 and a beta of 1.52. The business has a 50 day simple moving average of $16.47 and a 200 day simple moving average of $13.18.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. On average, equities research analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.